

Jane E Rogers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5877393/publications.pdf>

Version: 2024-02-01

86
papers

1,315
citations

643344

15
h-index

445137

33
g-index

86
all docs

86
docs citations

86
times ranked

2142
citing authors

#	ARTICLE	IF	CITATIONS
1	Esophageal cancer: Is the CROSS strategy ready for history books?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 901-905.	0.4	3
2	Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 34-42.	1.2	9
3	Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 181-202.	0.8	4
4	Pharmaceutical advances in the treatment of gastric adenocarcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , 1-11.	0.9	0
5	Prognostic factors associated with survival in patients with pancreatic cancer treated on early phase immune-checkpoint inhibitor clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 577-577.	0.8	0
6	Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing?. <i>Oncology</i> , 2022, 100, 182-187.	0.9	0
7	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , 2022, 5, e2213588.	2.8	10
8	The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 30-30.	0.4	1
9	Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 273, 751-757.	2.1	8
10	Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. <i>Oncology</i> , 2021, 99, 659-664.	0.9	2
11	Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2268-2274.	0.6	0
12	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. <i>JCO Oncology Practice</i> , 2021, 17, 607-614.	1.4	7
13	Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience. <i>Supportive Care in Cancer</i> , 2021, 29, 7351-7354.	1.0	8
14	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. <i>Cancer Medicine</i> , 2021, 10, 5041-5050.	1.3	35
15	Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant. <i>Clinical Colorectal Cancer</i> , 2021, 20, 273-278.	1.0	4
16	Pharmacotherapy for unresectable metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, , 1-10.	0.9	1
17	Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. <i>Cancers</i> , 2021, 13, 420.	1.7	3
18	The reality of early-onset colorectal cancer: highlighting the needs in a unique but emerging population. <i>Digestive Medicine Research</i> , 2021, 4, 63-63.	0.2	7

#	ARTICLE	IF	CITATIONS
19	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. <i>Gut</i> , 2020, 69, 18-31.	6.1	94
20	Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. <i>Annals of Surgery</i> , 2020, 272, 311-318.	2.1	14
21	Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 901-908.	1.1	7
22	Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. <i>Oncology</i> , 2020, 98, 542-548.	0.9	5
23	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	1.0	3
24	Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 5406-5415.	1.3	9
25	Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 55-60.	0.6	5
26	Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. <i>Oncology</i> , 2020, 98, 289-294.	0.9	10
27	Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. <i>Medicine (United States)</i> , 2020, 99, 1478-1484.	1.4	14
28	Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. <i>Pancreatology</i> , 2020, 20, 501-504.	0.5	31
29	Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. <i>Gastric Cancer</i> , 2020, 23, 904-912.	2.7	15
30	Recent advances in treating oesophageal cancer. <i>F1000Research</i> , 2020, 9, 1189.	0.8	50
31	Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. <i>Oncology</i> , 2020, 98, 884-888.	0.9	0
32	Why should localized gastric adenocarcinoma patients fare poorly after adjunctive therapy compared to surgery alone?. <i>Chinese Clinical Oncology</i> , 2020, 9, 2-2.	0.4	1
33	Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2805-2806.	0.8	2
34	Pharmacotherapeutic considerations for elderly patients with colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2139-2160.	0.9	2
35	Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. <i>Oncology</i> , 2019, 96, 252-258.	0.9	4
36	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 523-534.	0.9	3

#	ARTICLE	IF	CITATIONS
37	A retrospective analysis of antibiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, e15781-e15781.	0.8	5
38	Paratracheal lymph node metastasis in operable localized esophageal and gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, e15526-e15526.	0.8	0
39	The prognostic factors associated with long-term survival in the patients with synchronous oligometastatic esophageal adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, e15523-e15523.	0.8	3
40	Value appraisal of FDA approved cancer drugs over the past decade.. Journal of Clinical Oncology, 2019, 37, e18385-e18385.	0.8	0
41	Reporting of patient (pt) characteristics (c) and use of stratification factors (SF) in phase III trials for metastatic colorectal cancer (mCRC): Urgent need for standardization.. Journal of Clinical Oncology, 2019, 37, e15055-e15055.	0.8	0
42	Abstract B36: Maintenance chemotherapy after chemoradiation in patients with locally advanced pancreatic cancer. , 2019, , .		1
43	Abstract B35: Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. , 2019, , .		0
44	A Case Reportâ€”Stevens-Johnson Syndrome as an Adverse Effect of Capecitabine. Journal of Gastrointestinal Cancer, 2018, 49, 349-350.	0.6	6
45	Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. British Journal of Cancer, 2018, 118, 331-337.	2.9	10
46	Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Targeted Oncology, 2018, 13, 99-106.	1.7	10
47	Potentially curable gastric adenocarcinoma treated without surgery. European Journal of Cancer, 2018, 98, 23-29.	1.3	8
48	Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology, 2018, 94, 345-353.	0.9	1
49	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 446-453.	5.1	322
50	Pharmacotherapy of Anal Cancer. Drugs, 2017, 77, 1519-1530.	4.9	6
51	101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology, 2017, 93, 243-248.	0.9	13
52	Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Medical Oncology, 2017, 34, 135.	1.2	5
53	Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Annals of Surgical Oncology, 2017, 24, 2291-2301.	0.7	8
54	Patient considerations in metastatic colorectal cancer – role of panitumumab. OncoTargets and Therapy, 2017, Volume 10, 2033-2044.	1.0	8

#	ARTICLE	IF	CITATIONS
55	Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 347-351.	0.6	30
56	Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. <i>Oncotarget</i> , 2017, 8, 79356-79365.	0.8	3
57	Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 499-505.	0.6	16
58	A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 173-179.	2.3	11
59	Epidermal growth factor receptor inhibition in metastatic anal cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 804-808.	0.7	26
60	The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. <i>Oncologist</i> , 2016, 21, 563-570.	1.9	40
61	The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. <i>Oncology</i> , 2016, 90, 239-247.	0.9	44
62	Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. <i>Oncology</i> , 2016, 91, 55-60.	0.9	11
63	Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. <i>Oncology</i> , 2016, 90, 10-20.	0.9	4
64	NCI9673: A multi-institutional eTCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3503-3503.	0.8	12
65	Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. <i>Oncology</i> , 2015, 89, 305-310.	0.9	5
66	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , 2015, 20, 1247-1252.	1.9	28
67	Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. <i>Oncology</i> , 2015, 89, 65-69.	0.9	4
68	Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency. <i>Supportive Care in Cancer</i> , 2015, 23, 1657-1662.	1.0	19
69	Geographic Distribution of Regional Metastatic Nodes Affects the Outcome of Trimodality-Eligible Patients with Esophageal Adenocarcinoma. <i>Oncology</i> , 2015, 88, 332-336.	0.9	1
70	Ramucirumab for the treatment of gastroesophageal cancers. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 737-746.	0.5	3
71	Early versus Delayed Therapy of Advanced Gastric Cancer Patients - Does It Make a Difference?. <i>Oncology</i> , 2015, 89, 215-220.	0.9	4
72	18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. <i>European Journal of Cancer</i> , 2015, 51, 2545-2552.	1.3	48

#	ARTICLE	IF	CITATIONS
73	Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 678-678.	0.8	9
74	Assessing the impact of a targeted electronic medical record intervention on the use of growth factor in cancer patients. Journal of Community and Supportive Oncology, 2015, 13, 113-116.	0.1	5
75	Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. Journal of Gastrointestinal Oncology, 2015, 6, E82-5.	0.6	4
76	Isotretinoin maintenance therapy for glioblastoma: A retrospective review. Journal of Oncology Pharmacy Practice, 2014, 20, 112-119.	0.5	6
77	Atypical Metastatic Presentations in Colorectal Cancer: A Case Series. Clinical Colorectal Cancer, 2014, 13, e1-e4.	1.0	9
78	A Case Reportâ€”Treatment of Metastatic Colorectal Cancer in a Patient on Hemodialysis. Journal of Gastrointestinal Cancer, 2014, 45, 161-165.	0.6	3
79	Cetuximab in Refractory Squamous Cell Carcinoma of the Anal Canal. Journal of Gastrointestinal Cancer, 2014, 45, 198-200.	0.6	7
80	MD Anderson experience with off-study regorafenib in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 635-635.	0.8	2
81	The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget, 2014, 5, 11133-11142.	0.8	102
82	Second-line systemic treatment for advanced cholangiocarcinoma. Journal of Gastrointestinal Oncology, 2014, 5, 408-13.	0.6	34
83	Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointestinal Cancer Research: GCR, 2014, 7, 65-8.	0.8	4
84	Differentiation syndrome in patients with acute promyelocytic leukemia. Journal of Oncology Pharmacy Practice, 2012, 18, 109-114.	0.5	47
85	Colorectal cancer during pregnancy or postpartum: Case series and literature review. Obstetric Medicine, 0, , 1753495X2110412.	0.5	4
86	Metastatic or Locally Recurrent Anal Squamous Cell Carcinoma (SCAC): Current Clinical Trial Landscape and Novel Approaches. Cancer Management and Research, 0, Volume 14, 2065-2077.	0.9	4